Shares in Stratagene rose 15.9 percent for the trading week ended Tuesday, a week after its shares had gained 17.4 percent. The firm had seen its shares slump to a 52-week low of $3.98 in the month leading up to the turnaround, but investors are clearly showing that they believe the stock was undervalued. The firm’s shares, however, have a long way to go before matching the 52-week high of $11.41.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.